Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Inclusion Criteria: Additional criteria check may apply for qualification: * Glycated hemoglobin(HbA1c) of ≥6.5% and ≤12.0% * eGFR of ≥30 mL/min/1.73m2 and \<90 mL/min/1.73m2 * The median UACR of the first morning void urine samples is ≥300 mg/g Cr and ≤5000 mg/g Cr * Patients who are taking on angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) * Patients who are under dietary management and taking therapeutic exercise for diabetes Exclusion Criteria: Additional criteria check may apply for qualification: * Type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes * A diagnosis of non-diabetic renal disease * Hereditary glucose-galactose malabsorption or primary renal glucosuria * Class IV heart failure symptoms according to New York Heart Association (NYHA) functional classification * Severe hepatic disorder or severe renal disorder * Blood potassium level \>5.5 mmoL/L * Stable blood pressure (diastolic blood pressure (DBP) ≥100mmHg or systolic blood pressure (SBP) ≥180mmHg)